SPECIALIZED PGM OF RESEARCH EXCELLENCE/PROSTATE CANCER

这个孢子应用程序(P-50)是为了支持高度交互和 约翰霍普金斯大学医疗机构的多学科研究将影响 关于人类前列腺癌的控制。这个孢子涉及18个互动 组件可分类为：a.)分子生物学和分子生物学研究 人类前列腺癌的细胞机制。1)分子遗传学 研究(W.Isaacs)；确定遗传联系的家族性研究(T. 比蒂/P·沃尔什/W·艾萨克)；高分辨率细胞遗传学研究(C. 格里芬)；4)雄激素受体基因结构和功能的分子分析 功能(E.兵营)；5.前列腺癌骨骼的分子机制研究进展 转移(H.Reddi)；核结构和DNA的研究 组织(D.Coffey)。B.人类前列腺癌的早期检测和 预测研究：7.)前列腺癌高危男性的识别 (B.Carter/J.Fozard)；8.用于预测临床的定量病理学 结果(J·爱泼斯坦)；转移抑制基因的鉴定(J. 艾萨克斯)。C.新疗法的开发。10.)识别新的 拓扑异构酶药物靶点(W.Nelson/L.Liu)；前列腺癌基因 动物模型中的靶向免疫疗法(D.Pardoll/R.Muligan)；基因 人前列腺癌细胞的转移疗法(J.Simons/R.Mulrigan)； 13.)前列腺癌和前列腺癌转基因新模型的建立 自身免疫(D.Pardoll/W.Nelson)；D.特殊资源的开发。 14.)人类前列腺癌新的异种动物移植模型(J.Isaacs)；15. 建立前列腺癌组织和DNA数据库(J.Epstein/W. 艾萨克)；16.)前列腺癌研究生物统计学核心(S. Piantadosi)；17.)成立了一个通讯和教育股，负责 在全国范围内迅速传播前列腺癌和 参加全国前列腺研究夏季课程(D.Coffey)。18.)引航员 项目开发到a。)研究前列腺癌的病毒方面(W. Burns)和B.)细胞程序性死亡的核磁共振波谱研究 前列腺癌(J.格利克森) 这些多学科项目从家庭研究延伸到就业 近距离利用人前列腺癌细胞进行基因治疗的新方法 与麻省理工学院的理查德·穆里根博士合作。这18个组件 孢子将主要关注人类前列腺癌，不同于 计划项目拨款，因为每个单元都被设计为既高度 交互的和依赖于孢子内的其他程序的。该计划 旨在促进将这些发现快速转换为 人类前列腺癌的控制。

This SPORE application (P-50) is to support a highly interactive and multidisciplinary study at the Johns Hopkins Medical Institutions to impact on control of human prostate cancer. This SPORE involves 18 interactive components that can be categorized into: A.) Studies of the Molecular and Cellular Mechanisms in Human Prostate Cancer. 1.) Molecular genetic studies (W. Isaacs); 2.) Familial studies to identify genetic linkages (T. Beaty/P. Walsh/W. Isaacs); 3.) High resolution cytogenetic studies (C. Griffin); 4.) Molecular analysis of androgen receptor gene structure and function (E. Barrack); 5.) Molecular mechanisms in prostate cancer bone metastasis (H. Reddi); 6.) Studies of nuclear structure and DNA organization (D. Coffey). B. Early Human Prostate Cancer Detection and Prediction Studies: 7.) Identification of men at risk for prostate cancer (B. Carter/J. Fozard); 8.) Quantitative pathology to predict clinical outcome (J. Epstein); 9.) Identification of metastatic suppressor genes (J. Isaacs). C. Development of New Therapies. 10.) Identification of new topoisomerase drug targets (W. Nelson/L. Liu); 11.) Prostate cancer gene targeted immunotherapy in animal models (D. Pardoll/R. Mulligan); 12.) Gene transfer therapy in human prostate cancer cells (J. Simons/R. Mulligan); 13.) Development of new transgenic models of prostate cancer and prostate autoimmunity (D. Pardoll/W. Nelson); D. Development of Special Resources. 14.) New animal xenograft models of human prostate cancer (J. Isaacs); 15.) Establishment of a prostate cancer tissue and DNA bank (J. Epstein/W. Isaacs); 16.) Biostatistical core for prostate cancer studies (S. Piantadosi); 17.) Formation of a communication and education unit for the rapid national dissemination of research information on prostate cancer and for a national summer course on prostate research (D. Coffey). 18.) Pilot Project Development to a.) study viral aspects of prostate cancer (W. Burns) and b.) NMR spectroscopy studies of programmed cell death in prostate cancer (J. Glickson). These multidisciplinary programs extend from familial studies to employing new methods in gene therapy utilizing human prostate cancer cells in close collaboration with Dr. Richard Mulligan at MIT. These 18 components of the SPORE will focus primarily on human prostate cancer, differing from a Program Project Grant as each unit is designed to be both highly interactive and dependent on other programs within the SPORE. The program is designed to facilitate the rapid translation of these findings into the control of human prostate cancer.